R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 37.25 PLN -0.67%
Market Cap: 861.2m PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Wall Street
Price Targets

RVU Price Targets Summary
Ryvu Therapeutics SA

Wall Street analysts forecast RVU stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RVU is 82.06 PLN with a low forecast of 69.19 PLN and a high forecast of 104.27 PLN.

Lowest
Price Target
69.19 PLN
86% Upside
Average
Price Target
82.06 PLN
120% Upside
Highest
Price Target
104.27 PLN
180% Upside
Ryvu Therapeutics SA Competitors:
Price Targets
GENO
Genovis AB
64% Upside
AZTA
Azenta Inc
9% Upside
603127
Joinn Laboratories China Co Ltd
10% Downside
RGEN
Repligen Corp
27% Upside
PPGN
PolyPeptide Group AG
22% Upside
CTKB
Cytek Biosciences Inc
25% Upside
300347
Hangzhou Tigermed Consulting Co Ltd
28% Upside
BRKR
Bruker Corp
21% Upside

Revenue
Forecast

Revenue Estimate
Ryvu Therapeutics SA

For the last 8 years the compound annual growth rate for Ryvu Therapeutics SA's revenue is 2%. The projected CAGR for the next 4 years is 25%.

2%
Past Growth
25%
Estimated Growth
Estimates Accuracy
-36%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Ryvu Therapeutics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-4%
Average Miss

Net Income
Forecast

Net Income Estimate
Ryvu Therapeutics SA

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-37%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RVU's stock price target?
Price Target
82.06 PLN

According to Wall Street analysts, the average 1-year price target for RVU is 82.06 PLN with a low forecast of 69.19 PLN and a high forecast of 104.27 PLN.

What is Ryvu Therapeutics SA's Revenue forecast?
Projected CAGR
25%

For the last 8 years the compound annual growth rate for Ryvu Therapeutics SA's revenue is 2%. The projected CAGR for the next 4 years is 25%.

Back to Top